ative medication.</p>

<p><em>Zolmitriptan</em></p>

<p>In a single open-label trial, oral zolmitriptan 10 mg demonstrated efficacy for <span class="SearchCriteria">cluster</span> attacks; however, the adverse profile was significant. No data are available at this time with the nasal spray formulation.</p>

<p><em>Dihydroergotamine (DHE)</em></p>

<p>DHE administered by nasal spray or injection can decrease the intensity of individual attacks and may also completely abort the pain. Intravenous injec